Skip to main content
Fig. 2 | AAPS Open

Fig. 2

From: Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections

Fig. 2

Comparison between baseline-corrected UV-Vis spectra for Yomesan at the 30 s time point for initial Yomesan niclosamide-equivalent concentrations of 300 µM, 600 µM, and 1 mM in pH 9.35 Tris buffer. A UV-Vis spectra showing the “impurity” peak indicated (black arrow) at 345 nm, and the expected double niclosamide peaks indicated (gray arrows) at 333 and 377 nm. B Relative absorbance at 333 nm vs. initial added Yomesan niclosamide-equivalent concentration (µM) reveals a linear dependence to the “impurity” absorbance with an intercept at an Absorbance of 0.0292 AU, which would be equivalent to a niclosamide concentration of 1.05 µM. C Comparison between the UV-Vis spectra for the 30s “impurity” for 1 mM Yomesan niclosamide and a 12.5 µM vanillin solution, both in pH 9.35 Tris buffer

Back to article page